TRVN: trevena.com Price to Earnings Adjusted for Growth Rate
Non-opioid developments and a strong scientific foundation drive the growth of Trevena, Inc. (TRVN). In GURU.Markets, the growth-adjusted P/E confirms this potential, where 0.00 shows the current value of the metric. Management's focus on the commercialization of clinic products complements the strategy, while the neutral geopolitical status of medicine within the US legal framework ensures stability.
Analytical breakdowns for Trevena, Inc. (TRVN)
- share price and consensus valuation forecast:
- market capitalization information:
- shareholders' equity book value data:
- business debt structure and liquidity details:
- financial results and valuation multiples details:
TRVN - Net Profit|Future Profit Trevena, Inc.|TRVN - Price to Earnings Ratio|Market Cap to Projected Earnings Trevena Inc|TRVN - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Trevena, Inc|TRVN - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Trevena|TRVN - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months trevena.com|TRVN - Earnings per share growth in current year|Projected earnings per share growth rate for next year Trevena, Inc.
Summary company analytics:Trevena Inc., TRVN
The PEG ratio compares the market value of earnings to their growth rate, allowing for a determination of an asset's fair valuation relative to its expansion. The implementation of software research automation at Trevena, Inc. (TRVN) accelerates data digitization, which is reflected in the P/E ratio relative to EPS dynamics, signaling potential undervaluation and confirming the high resilience of investment capital.
Competing companies
BIIB (Biogen Inc) - Growth-Adjusted Payback Ratio|PEG Multiple NBIX (Neurocrine Biosciences Inc)|Regencell Corp (RGC) - Price to Earnings Adjusted for Growth Rate|AXSM: Price/Earnings to Growth Multiple|ACAD: Price/Earnings to Growth Ratio|XENE: PEG Multiple|Price to Earnings Adjusted for Growth Rate Viking Therapeutics Inc (VKTX)|Price/Earnings to Growth Ratio Supernus Pharma|Growth-Adjusted P/E Ratio CPRX (Catalyst Corp)|PEG Multiple DNLI|PEG Multiple harmonybiosciences.com (HRMY)|Biohaven - Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio AMLX|Trevi Pharma - PEG Multiple|Growth-Adjusted Market Cap to Net Income Praxis Corp PRAX|Anavex Life Sciences (AVXL) - Price/Earnings to Growth Ratio|Growth-Adjusted P/E Ratio CBLL|PRTA (Prothena Corporation plc) - PEG Multiple|Price/Earnings to Growth Multiple Alector Therapeutics (ALEC)|Price/Earnings to Growth Multiple ANNX (Annexon Inc.)|Growth-Adjusted Market Cap to Net Income omeros.com|Neurogene Inc. - Price/Earnings to Growth Multiple|Company Value to Earnings Growth Ratio ACIU (acimmune.com)|VYGR - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio NMRA (Neumora)|SCLX (Scilex Holding Co.) - Price/Earnings to Growth Multiple|TVGN (Tevogen Bio Inc.) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Ratio Alpha Cognition Inc|Growth-Adjusted P/E Ratio CGTX (cogrx.com)|Price/Earnings to Growth Ratio Inhibikase Therapeutics, Inc. (IKT)|Cassava Sciences Inc - Growth-Adjusted P/E Ratio|PEG Multiple ASRT (Assertio)|Coya Therapeutics Inc (COYA) - Price to Earnings Adjusted for Growth Rate|VTGN: Price/Earnings to Growth Multiple|OVID - PEG Multiple|Acumen Pharmaceuticals, Inc. (ABOS) - Price/Earnings to Growth Ratio|CervoMed, Inc. - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Alterity Therapeutics Ltd.|Price to Earnings Adjusted for Growth Rate Clene Nanomedicine CLNN|Price/Earnings to Growth Multiple PEPG (PepGen Inc.)|Company Value to Earnings Growth Ratio JUNS|Price/Earnings to Growth Ratio Relmada Therapeutics, Inc. RLMD|Growth-Adjusted Payback Ratio ANVS|Grace Tx - PEG Multiple|Price to Earnings Adjusted for Growth Rate Firefly Neuro|KLTO (anewmeds.com) - Price/Earnings to Growth Multiple|NRSN (NeuroSense Therapeutics Ltd.) - Price/Earnings to Growth Ratio|RVPH (Reviva Pharmaceuticals Holdings, Inc.) - PEG Multiple|Price to Earnings Adjusted for Growth Rate MetaVia, Inc. MTVA|Price/Earnings to Growth Ratio NeurAxis, Inc (NRXS)|heliusmedical.com - Growth-Adjusted P/E Ratio|PEG Multiple PASG (Passage Bio)|PEG Multiple Neuphoria Therapeutics, Inc. NEUP|NERV: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio ATHA (Athira Pharma Inc)|ADXN: PEG Multiple|ALZN - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio Cyclerion Therapeutics Inc.|Growth-Adjusted P/E Ratio PTIX (Protagenic)|PEG Multiple KTTA|Price/Earnings to Growth Multiple cortigent.com CRGT|Avenue Therapeutics, Inc - Price/Earnings to Growth Multiple|Growth-Adjusted Market Cap to Net Income BrainStorm Cell Therapeutics Inc. (BCLI)|CARA: Price/Earnings to Growth Multiple|chromocell.com - Company Value to Earnings Growth Ratio|eliemtx.com (ELYM) - Price/Earnings to Growth Ratio|Intra-Cellular Therapies, Inc. - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Multiple LBPH|Price/Earnings to Growth Ratio MRNS|Price/Earnings to Growth Ratio NKGen Biotech, Inc. (NKGN)|neurobopharma.com - Growth-Adjusted P/E Ratio|Price/Earnings to Growth Ratio Sage Therapeutics SAGE|SNPX: Growth-Adjusted P/E Ratio|Vigil Neuro - PEG Multiple|Price to Earnings Adjusted for Growth Rate Anew Medical Inc.|CERE (Cerevel Therapeutics) - Price/Earnings to Growth Multiple
